AllianceBernstein LP recently announced the acquisition of new stake in Genmab ADR (NASDAQ:GMAB). The institutional investor has increased its shareholding in the Healthcare company by 16.22% to 9.52 million shares with purchase of 1.33 million shares. This fresh investment now brings its stake to 1.44% valued currently at $300.78 million. In addition, Capital Research & Management Co raised its holdings by 0.12 million to 4.32 million shares. And Harding Loevner LP has lifted its position by 1,805.91% or 3.04 million shares – to 3.2 million shares.
With over 0.41 million Genmab ADR (GMAB) shares trading Friday and a closing price of $31.44 on the day, the dollar volume was approximately $12.82 million. The shares have shown a negative half year performance of -17.70% and its price on 12/22/23 gained nearly 1.19%. Currently, there are 653.72M common shares owned by the public and among those 653.15M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 29 analysts who have offered their price forecasts for GMAB have a consensus price objective of $2811.32. The analysts have set the share’s price value over the next 12 months at a high of $3738.69 and a low of $2000.00. The average price target is 22.85% above its recent price level and an upside to the estimated low will see the stock gain 98.43% over that period. But an upside of 99.16% will see the stock hit the forecast high price target while median target price for the stock is $2850.00.
The top 3 mutual fund holders in Genmab ADR are AB Large Cap Growth Fund, iShares Biotechnology ETF, and Vanguard Health Care Fund. AB Large Cap Growth Fund owns 4.06 million shares of the company’s stock, all valued at over $128.44 million. The company bought an additional 1.35 million shares recently to bring their total holdings to about 0.62% of the shares outstanding. iShares Biotechnology ETF sold 17970.0 shares to see its total holdings shrink to 3.23 million shares valued at over $101.97 million and representing 0.49% of the shares outstanding. Vanguard Health Care Fund now owns shares totaling to 0.35% of the shares outstanding.
Shares of Genmab ADR (NASDAQ: GMAB) opened at $31.02, down -$0.05 from a prior closing price of $31.07. However, the script later moved the day high at 31.61, up 1.19%. The company’s stock has a 5-day price change of 1.88% and -13.28% over the past three months. GMAB shares are trading -25.81% year to date (YTD), with the 12-month market performance down to -27.12% lower. It has a 12-month low price of $27.74 and touched a high of $43.66 over the same period. GMAB has an average intraday trading volume of 863.96K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.14%, 2.03%, and -14.01% respectively.
Institutional ownership of Genmab ADR (NASDAQ: GMAB) shares accounts for 7.29% of the company’s 653.72M shares outstanding. Mutual fund holders own 3.26%, while other institutional holders and individual stakeholders account for 3.95% and — respectively.
It has a market capitalization of $20.54B and a beta (3y monthly) value of 0.87. The stock’s trailing 12-month PE ratio is 33.33, while the earnings-per-share (ttm) stands at $0.94. The company has a PEG of 2.49 and a Quick Ratio of 11.36 with the debt-to-equity ratio at 0.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.64% over the week and 1.76% over the month.
Analysts forecast that Genmab ADR (GMAB) will achieve an EPS of $3.98 for the current quarter, $2.7 for the next quarter and $15.47 for 2024. The lowest estimate earnings-per-share for the quarter is $3.11 while analysts give the company a high EPS estimate of $5.93. Comparatively, EPS for the current quarter was $0.12 a year ago. Earnings per share for the fiscal year are expected to decrease by -8.69%, and 11.43% over the next financial year. EPS should shrink at an annualized rate of 13.40% over the next five years, compared to 34.10% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 29 brokerage firm advisors rate Genmab ADR (GMAB) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 13 Wall Street analysts polled rate the stock as a buy, while 10 of the 29 advise that investors “hold,” and 2 rated it as a “Sell.”
